StockIQpro
NASDAQ:MIRM

Mirum Pharmaceuticals, Inc.

Track all markets on TradingView
Track all markets on TradingView

Mirum Pharmaceuticals, Inc.'s revenue grew 54.7% in fiscal 2025 to $521.3M while operating margin rose to −4.2%, its highest in 5 years. Free cash flow was $54.9M, 10.5% of revenue, and the diluted share count rose 5.6%.Summary generated from Mirum Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Feb 25, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$521.3M
Revenue growth+54.7%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−4.2%
Net margin−4.5%
ROICn/a
Return on equity−8.6%
Debt / equityn/a
Free cash flow$54.9M
FCF margin10.5%
Share count change+5.6%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue1977186337521
Operating income−173−131−109−88−22
Net income−84−136−163−88−23
Free cash flow−133−120−71955

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations